Augmedix Announces Inaugural AI Advisory Council Members
21 September 2023 - 1:00PM
Augmedix (Nasdaq: AUGX), a healthcare technology company that
delivers industry-leading, ambient medical documentation and data
solutions, announced the appointment of its inaugural AI Advisory
Council members. The council was established to guide Augmedix’s
continued development and usage of artificial intelligence (AI)
throughout its business responsibly and ethically.
The council is composed of a diverse group of
experts, including leading researchers in AI, to advise on the
development of new technologies for natural language processing
(NLP) and intelligent user interfaces (IUI); bioinformaticians to
speak to the appropriate and best use of these technologies in
clinical settings; executives from the healthcare systems that will
benefit from efficient, structured medical note taking; and
professional societies that contribute to government and industrial
policies governing AI in healthcare.
The council is led by Joe Marks, Ph.D., a former
Augmedix board member who served as director of the Company from
2020 until 2023. Dr. Marks was previously the Executive Director of
Carnegie Mellon University’s Center for Machine Learning and Health
and has established himself as a technological innovator in seven
different industries over the past 30 years.
Council members are esteemed professionals and
leaders from various fields and are appointed for 18 months. The
newly appointed members of the council are:
- Julia Adler-Milstein, Ph.D., Chief
of the Division of Clinical Informatics and Digital Transformation
at University of California San Francisco
- Albert Chan, M.D., Chief Digital
Health Officer, Sutter Health
- John Chelico, M.D., M.A., FACP,
FAMIA, System CMIO for CommonSpirit Health
- John Doulis, M.D., VP Data Services
and Technology Innovation at HCA Healthcare
- Jesse Ehrenfeld, M.D., MPH,
President of the American Medical Association
- Joe Marks, Ph.D., AI Advisory
Council Chair
- Eric Nyberg, Ph.D., Professor at
Carnegie Mellon University School of Computer Science Language
Technologies Institute
- Lisa Rotenstein, M.D., MBA, MSc,
Assistant Professor at Harvard Medical School and Medical Director
of Population Health at Brigham and Women’s Hospital
- Sameer Singh, Ph.D., Associate
Professor of Computer Science at UC Irvine
- Alex Stinard, M.D., Healthcare
Information Technology Consultant at HCA Healthcare
“As Augmedix continues to stay at the forefront
of innovation, it is vital that we have meaningful discourse to
address potential concerns with the adoption of AI in healthcare,”
said Augmedix CEO Manny Krakaris. “The AI Advisory Council will
provide our leadership and product innovation teams with
evaluations of opportunities and risks of technological
advancements in the healthcare space, along with strategic guidance
pertaining to our use of generative AI.”
As more healthcare organizations are sharing
concerns about the responsible adoption of AI, Augmedix is leading
the way with this advisory council to ensure that issues related to
transparency, privacy and safety are addressed by a variety of
expert perspectives.
“We are thrilled to be working with this group
of insightful and experienced thought leaders,” said Marks. “AI
technology is evolving rapidly and in surprising ways, so it is
important to be informed by all the varied perspectives that we
have on the council.”
About AugmedixAugmedix (Nasdaq:
AUGX) delivers industry-leading, ambient medical documentation and
data solutions to healthcare systems, physician practices,
hospitals, and telemedicine practitioners.
Augmedix is on a mission to help clinicians and
patients form a human connection at the point of care, through
technology that works in the background and does not interfere with
the clinician-patient encounter. Augmedix’s proprietary Notebuilder
Platform extracts relevant data from natural clinician-patient
conversations and converts that data into medical notes in real
time, which are seamlessly transferred to the EHR. The company’s
platform uses automatic speech recognition, natural language
processing, including large language models, and medical
documentation specialists to generate accurate and timely medical
notes.
Leveraging this platform, Augmedix’s products
relieve clinicians of administrative burden, in turn, reducing
burnout and increasing both clinician and patient satisfaction.
Augmedix is also leading the revolution in transforming
point-of-care information into valuable structured data that can
drive lower revenue cycle management costs, higher reimbursement
levels and deliver important clinical feedback to the point of
care.
Augmedix is headquartered in San Francisco, CA,
with offices around the world. To learn more, visit
www.augmedix.com.
Contact Information
Investors:Matt Chesler, CFAFNK IR646-809-2183augx@fnkir.com
investors@augmedix.com
Media:Kaila GrafemanAugmedixpr@augmedix.com
Forward-Looking Statements
This press release contains “forward-looking
statements” that involve a number of risks and uncertainties. Words
such as “believes,” “may,” “will,” “estimates,” “potential,”
“continues,” “anticipates,” “intends,” “expects,” “could,” “would,”
“projects,” “plans,” “targets,” “excited,” “optimistic,” and
variations of such words and similar expressions are intended to
identify forward-looking statements. Such forward-looking
statements include, without limitation, statements regarding the
development of AI in a responsible and ethical way, the
responsibilities of the AI Advisory Council, the role the AI
Advisory Council will play to ensure that issues related to
transparency, privacy and safety are addressed by a variety of
expert perspectives, the benefits of the AI Advisory Council to
Augmedix, Augmedix leading the way with its AI Advisory Council,
and the importance of balancing the want to innovate with the need
to review and evaluate these technologies. Actual results could
differ materially from those stated or implied in forward-looking
statements due to a number of factors, including but not limited
to, risks detailed in our most recent Form 10-K filed with the U.S.
Securities and Exchange Commission on April 17, 2023, as well as
other documents that may be filed by us from time to time with the
U.S. Securities and Exchange Commission. The forward- looking
statements included in this press release represent our views as of
the date of this press release. We undertake no intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
Augmedix (NASDAQ:AUGX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Augmedix (NASDAQ:AUGX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024